Velcura Therapeutics and GeneGo Enter Multi Year Agreement
News Nov 10, 2005
All Velcura employees will have access to the MetaCore database and suite of software tools for three years to focus on bone related disease research.
Velcura researchers will be using MetaCore for analysis of gene expression, proteomic, and other data related to human bone formation.
“We spent quite some time evaluating systems biology platforms and were impressed by the depth and breadth of the MetaCore knowledge base.” said Dr. Daniel Chagnovich, Director of Research Operations for Velcura.
“MetaCore has impressive coverage of signaling and metabolic pathways and in-depth disease and tissue-specific data that is invaluable for our research.”
“In addition, MetaCore has a flexible and powerful front-end that allows our bench scientists to integrate multiple data streams and algorithms to fully mine our bone therapy data.”
“We are very pleased to have Velcura as a new GeneGo customer,” said Julie Bryant, Vice President of Business Development at GeneGo.
“High-throughput experimentation matures fast, and nowadays researchers deal not only with gene expression, but also individual DNA variability, protein abundance and isoforms content, changes in body liquid metabolic profiles and high content drug screening data.”
“To be able to visualize and analyze such diverse datasets, we have built a comprehensive database of direct interactions between genes, proteins, enzymes, metabolic by-products and cell-regulators in human and other mammals.”
“Velcura researchers will be able to directly access this content and use it in projects via their MetaCore license.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.